Minocycline has no clear role in the treatment of Mycobacterium abscessus disease [PublishAheadOfPrint]

Mycobacterium abscessus (Mab) causes difficult-to-treat pulmonary disease (Mab-PD). After the initial intravenous treatment, minocycline is recommended in the oral continuation phase of treatment. We determined minimum inhibitory concentrations, synergy and time-kill kinetics of minocycline against Mab. With MICs of 8-512 mg/l, rapid emergence of tolerance in time-kill assays and no synergy with other drugs used to treat Mab-PD, minocycline appears ineffective against Mab. These in vitro data question its role as a Mab-PD treatment modality.

https://ift.tt/2nB5EL6